Welcome to our dedicated page for Baird Medical news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical stock.
Baird Medical Investment Holdings Ltd (NASDAQ: BDMD) is closely associated with minimally invasive Microwave Ablation (MWA) technology for the treatment of benign and malignant tumors. The BDMD news page on Stock Titan aggregates company-specific updates so readers can follow how Baird Medical’s medical devices and minimally invasive treatment technologies are being used and introduced in clinical settings around the world.
News about Baird Medical often highlights clinical milestones, such as first procedures in new countries, successful thyroid and liver tumor ablations, and applications of its MWA systems in bone tumor cases. Releases also describe physician training initiatives, including advanced MWA training sessions and participation in international workshops focused on thyroid microwave ablation and thermal ablation techniques.
Another recurring theme in BDMD news is global expansion and regulatory progress. The company reports regulatory approvals and product registrations in markets such as Pakistan and Vietnam, as well as entry into countries including Egypt and Bangladesh. Announcements have also covered the establishment of a U.S. manufacturing base through a partnership with MPS Medical to support worldwide supply of its proprietary technologies.
Investors and healthcare professionals can use this news feed to monitor developments related to Baird Medical’s microwave ablation devices, its presence in leading hospitals and clinics, and its broader commercialization and training activities. For ongoing insight into BDMD stock from a news perspective, this page provides a focused view of the company’s clinical, regulatory, and operational updates.
Baird Medical (NASDAQ: BDMD) announced on January 7, 2026 that it received official product registrations from the Medical Device Board of Pakistan and the Ministry of Health of Vietnam. The company executed a Pakistan product launch at the Armed Forces Institute of Radiology & Imaging (AFIRI) under the professional guidance of Dr. Raza Raheem.
Vietnam registration expands Baird Medical's compliant footprint in Southeast Asia and supports its stated global commercialization strategy by enabling market entry and clinician access to its microwave ablation (MWA) technology.
Baird Medical (NASDAQ: BDMD) announced on Dec. 17, 2025 the establishment of a dedicated U.S. manufacturing base to support its global expansion.
The company said it partnered with California-based MPS Medical to create a centralized production hub in North America, shifting from an exporter model toward a comprehensive global medical technology provider. The facility is described as supplying Baird Medical's proprietary Microwave Ablation technologies to global markets and improving quality and supply chain efficiency. Recent commercial growth noted includes market penetrations in Indonesia and Malaysia.
Baird Medical (NASDAQ: BDMD) announced completion of an advanced Microwave Ablation (MWA) training session on Dec. 8, 2025 led by Dr. Emad Kandil.
The program trained Dr. Richard Harding of Arizona Endocrine Surgery with observation of three live MWA procedures, a hands-on component, and strategic planning for integrating MWA into his Phoenix practice. Dr. Harding received a Certificate of Completion, underscoring proficiency in MWA and supporting expanded patient access to non‑surgical thyroid treatment options in Arizona.
Baird Medical (NASDAQ: BDMD) named Mark Saxton as Chief Executive Officer of its U.S. subsidiary effective December 3, 2025. Mr. Saxton has more than 25 years of commercial leadership in medical devices and will lead U.S. sales, marketing, and market development as Baird Medical accelerates U.S. entry for its microwave ablation (MWA) platform.
His prior roles include scaling VNUS Medical Technologies (doubling U.S. revenue from $49M to > $100M before a $512M acquisition by Covidien), supporting NeuroPace through a $117M IPO, and repositioning Ceterix for a $105M acquisition by Smith + Nephew.
Baird Medical (NASDAQ: BDMD) announced its official launch into the Egyptian market on Nov 3, 2025 with a successful first microwave bone ablation at Ain Shams Specialized Hospital.
The procedure, performed by Dr. Amr Mahmoud, treated a 1 x 1.5 cm bone lesion in a 30-year-old male with left thigh pain and achieved full ablation and marked pain relief, illustrating the Baird MWA system's use in musculoskeletal applications beyond soft tissue.
Baird Medical (NASDAQ: BDMD) announced clinical adoption of its Microwave Ablation (MWA) system at Elk Medical, a private endocrinology practice in Brooklyn, New York, on Oct. 27, 2025. Dr. Kazeem performed nine MWA procedures treating large thyroid nodules as a non-surgical alternative. The clinic reported that these initial procedures have been successfully reimbursed by Medicare, which the company described as an encouraging early step toward broader patient access and potential economic viability for MWA therapy in a key U.S. market.
Baird Medical (NASDAQ: BDMD) announced the company’s first successful microwave ablation (MWA) liver tumor procedure in Bangladesh on Oct 23, 2025. The treatment was performed at USB Hospital in Uttara, Dhaka, by Dr. Mofazzal Sharif Rasel and team on a 65-year-old patient with a 6 cm liver tumor, who is reported to be recovering well. The event represents a commercial and clinical adoption milestone for Baird Medical in South Asia and underscores the company’s stated focus on expanding global access to minimally invasive tumor therapies through strategic clinician and institution partnerships.
Baird Medical (NASDAQ: BDMD) participated in an International Thyroid Microwave Ablation Workshop at Hospital Canselor Tuanku Muhriz (HCTM), National University of Malaysia on October 1–2, 2025.
Led by Proctor Dr. Shuhang Xu, endocrinologist at Jiangsu Provincial Hospital, with HCTM surgeons Dr. Adi Syazni and Prof. Shahrun Niza, the two-day program combined theoretical lectures, complex case discussions, and hands-on training with mannequins and live patients to advance physician MWA skills and support global adoption of minimally invasive therapy.
Baird Medical (NASDAQ: BDMD) participated in a two-day Thyroid Microwave Ablation Workshop at Hospital Canselor Tuanku Muhriz, National University of Malaysia on Oct 1–2, 2025.
The immersive program combined lectures, complex case discussions and hands-on training with mannequins and live patient cases led by Proctor Dr. Shuhang Xu and HCTM faculty Dr. Adi Syazni and Prof. Shahrun Niza. Baird Medical supplied expertise and support to advance physician skills in minimally invasive Microwave Ablation (MWA) and to promote wider clinical adoption of MWA therapy in the region.
Baird Medical (NASDAQ: BDMD) participated in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism held in Beijing on October 17-18, 2025 at the China-Japan Friendship Hospital.
Chaired by Prof. Ming'an Yu, the workshop featured live procedures, clinical exchanges, and advanced technique discussions. Baird Medical said its presence highlights a commitment to international collaboration, sharing best practices for Microwave Ablation (MWA), and advancing minimally invasive thyroid care.
FAQ
What is the current stock price of Baird Medical (BDMD)?
What is the market cap of Baird Medical (BDMD)?
